DCPH - Here's Why Deciphera Pharmaceuticals Lost 22.7% in March
Shares of Deciphera Pharmaceuticals (NASDAQ: DCPH) fell nearly 23% last month, according to data from S&P Global Market Intelligence. Investors are concerned that the company's long-awaited transition to commercial operations will be delayed by the coronavirus pandemic. It's not an unreasonable concern.
The company's lead drug candidate, ripretinib, is widely expected to earn marketing approval from the U.S. Food and Drug Administration (FDA) in advanced gastrointestinal stromal tumors (GIST). But the previously stated regulatory decision deadline of mid-August could be pushed back in light of the current situation. That realization has weighed on the pharma stock.
Image source: Getty Images.